Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
RESEARCH TOOLSreports
Total Valuation
Neuren Pharmaceuticals Limited has a market cap or net worth of $1.54B. The enterprise value is AU$1.41B.
Market Cap$1.54B
Enterprise ValueAU$1.41B
Share Statistics
Neuren Pharmaceuticals Limited has 127,154,755 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding127,154,755
Owned by Insiders0.03%
Owned by Institutions<0.01%
Financial Efficiency
Neuren Pharmaceuticals Limited’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee28.99M
Profits Per Employee19.64M
Employee Count8
Asset Turnover0.94
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuren Pharmaceuticals Limited is 20.08. Neuren Pharmaceuticals Limited’s PEG ratio is <0.01.
PE Ratio20.08
PS Ratio0.00
PB Ratio15.37
Price to Fair Value15.37
Price to FCF17.06
Price to Operating Cash Flow17.05
PEG Ratio<0.01
Income Statement
In the last 12 months, Neuren Pharmaceuticals Limited had revenue of 231.93M and earned 157.08M in profits. Earnings per share was 1.24.
Revenue231.93M
Gross Profit205.17M
Operating Income172.49M
Pretax Income205.14M
Net Income157.08M
EBITDA199.26M
Earnings Per Share (EPS)1.24
Cash Flow
In the last 12 months, operating cash flow was 119.51M and capital expenditures -25.00K, giving a free cash flow of 119.49M billion.
Operating Cash Flow119.51M
Free Cash Flow119.49M
Free Cash Flow per Share0.94
Dividends & Yields
Neuren Pharmaceuticals Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.09
52-Week Price Change-33.71%
50-Day Moving Average11.65
200-Day Moving Average13.50
Relative Strength Index (RSI)61.05
Average Volume (3m)810.71K
Important Dates
Neuren Pharmaceuticals Limited upcoming earnings date is Aug 26, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateAug 26, 2025
Ex-Dividend Date―
Financial Position
Neuren Pharmaceuticals Limited as a current ratio of 5.78, with Debt / Equity ratio of 0.00%
Current Ratio5.78
Quick Ratio5.78
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuren Pharmaceuticals Limited has paid 48.06M in taxes.
Income Tax48.06M
Effective Tax Rate0.23
Enterprise Valuation
Neuren Pharmaceuticals Limited EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Neuren Pharmaceuticals Limited has $213.17M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -$213.17M billion.
Cash & Marketable Securities$213.17M
Total DebtAU$0.00
Net Cash-$213.17M
Net Cash Per Share-$1.68
Tangible Book Value Per Share$1.61
Margins
Gross margin is 82.65%, with operating margin of 74.37%, and net profit margin of 67.73%.
Gross Margin82.65%
Operating Margin74.37%
Pretax Margin88.45%
Net Profit Margin67.73%
EBITDA Margin85.92%
EBIT Margin85.89%
Analyst Forecast
The average price target for Neuren Pharmaceuticals Limited is $26.22, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$26.22
Price Target Upside104.81% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-8.06%
EPS Growth Forecast-10.13%